Transcenta Therapeutics has announced a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., covering the use of Transcenta’s Highly Intensified Continuous Bioprocessing (HiCB) platform. The agreement enables EirGenix to access Transcenta’s continuous perfusion and hybrid continuous purification technologies, alongside
Pluri, Inc. has announced the expansion of its manufacturing agreement with Remedy Cell Ltd., building on a collaboration first signed in 2024. The agreement covers GMP manufacturing and process development activities delivered through Pluri’s CDMO division, PluriCDMO™, in support of
mAbxience has announced that the U.S. Food and Drug Administration has approved the Biologics License Application for two denosumab biosimilars developed in partnership with Amneal Pharmaceuticals. The approvals cover Boncresa™ (denosumab-mobz), a Prolia®-referenced biosimilar, and Oziltus™ (denosumab-mobz), an XGEVA®-referenced biosimilar.
FUJIFILM Corporation has announced the completion of a new biopharmaceutical contract development and manufacturing organisation (CDMO) facility at the Toyama Second Factory of FUJIFILM Toyama Chemical in Japan. The plant is the company’s first antibody drug manufacturing site in the
Symbiosis has announced the manufacture of its first 10,000-vial batch at the company’s new sterile manufacturing facility in Stirling, UK. The batch was produced for a long-standing client and supports the development of a cancer immunotherapy currently in Phase III
Samsung Biologics has announced that its wholly owned U.S. subsidiary has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK, securing the company’s first U.S.-based manufacturing site. The move expands Samsung Biologics’ global manufacturing footprint
Minaris has announced a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult) to develop delivery technologies for cell and gene therapies, with the aim of enabling more robust manufacturing processes, improved quality, and lower cost of goods. Minaris
AtomVie Global Radiopharma has announced a strategic partnership with Ionetix Corporation to enhance access to clinical-grade Actinium-225 (Ac-225) for radiopharmaceutical programmes worldwide. AtomVie operates as a contract development and manufacturing organisation (CDMO) specialising in GMP manufacturing and clinical supply of
Lifecore Biomedical, Inc. has announced that it has entered into a CDMO master services agreement with a new large global pharmaceutical customer. Under the agreement, the company will provide development services and conduct technology transfer activities for an injectable pharmaceutical
PharmaSource analysis of 732 industry announcements reveals massive investment in U.S. capacity, with partnerships dominating the news cycle and advanced therapy manufacturing reaching industrial scale The pharmaceutical contract manufacturing landscape underwent a fundamental readjustment in 2025, marked by record
